| Date | Title | Description |
| 02.11.2025 | Global week ahead: Is Novo Nordisk past ‘peak uncertainty’? | Danish pharmaceutical group Novo Nordisk will release its third-quarter earnings on Wednesday.
CNBC’s Charlotte Reed will travel to Copenhagen to speak with the company’s new CEO after a bumpy few months.
Despite this, Berenberg is positive... |
| 09.10.2025 | Expedition resupplies for phase 2 COPD voyage with $165M series A | Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding will fuel the Bay Area biotech’s DPP1 inhibitor EXPD-101 as it ventures into a study in patients with chronic obstruct... |
| 09.10.2025 | Expedition Therapeutics: $165 Million Series A Raised For Advancing DPP1 Inhibitor For COPD | Expedition Therapeutics, a biotechnology company dedicated to developing therapies for novel inflammatory and respiratory diseases, has closed an oversubscribed and upsized Series A financing round, raising $165 million. This financing roun... |
| 22.06.2024 | AKRO Investors Have the Opportunity to Lead Akero Therapeutics, Inc. Securities Fraud Lawsuit | NEW YORK, June 22, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of all purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AK... |
| 13.06.2024 | The Lustgarten Foundation Appoints Two New Board Members | To date, the foundation has invested more than $282M in high-risk, high-reward research to accelerate and expand life-saving treatment options.
Richard Barakat, MD, and Aaron Kantoff join the Lustgarten Foundation Board of Directors
WOODBUR... |
| 29.05.2024 | ROSEN, A LEADING LAW FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO | NEW YORK, May 29, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusiv... |
| 22.05.2024 | ROSEN, A RANKED AND LEADING FIRM, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO | NEW YORK, May 22, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusiv... |
| 14.05.2024 | ROSEN, SKILLED INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO | NEW YORK, May 14, 2024 /PRNewswire/ --
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusiv... |
| 07.05.2024 | ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Akero Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKRO | NEW YORK, May 7, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Akero Therapeutics, Inc. (NASDAQ: AKRO) between September 13, 2022 and October 9, 2023, both dates inclusive... |
| 08.03.2024 | Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | - |
| 07.03.2024 | Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology | - |
| 05.03.2024 | Akero Therapeutics Announces Pricing of Public Offering of Common Stock | - |
| 16.05.2023 | Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock | - |
| 16.06.2022 | Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million | $25 Million Equity Investment by Pfizer at $9.90 Per Share |
| 16.06.2022 | Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million | $25 Million Equity Investment by Pfizer at $9.90 Per Share
Term Loan Facility from Hercules Providing Up to $100 Million
If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024
SOUTH SAN FRANCIS... |
| 16.06.2022 | Akero Therapeutics Announces Two Financing Transactions with Pfizer Inc. and Hercules Capital, Inc. Providing Access to Up To $125 Million | $25 Million Equity Investment by Pfizer at $9.90 Per Share
Term Loan Facility from Hercules Providing Up to $100 Million
If Fully Drawn, Akero Cash Runway Extended One Full Year From Previously Announced Q3 2023 to Q3 2024
SOUTH SAN FRAN... |
| 24.02.2021 | Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH | |
| 12.11.2020 | Akero Therapeutics Reports Third Quarter 2020 Financial Results | |
| 16.10.2020 | Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH | |
| 31.03.2020 | Myovant grabs $40M upfront in regional deal for relugolix; Akero announces NASH success but Covid-19 delays | → Having just filed for the European approval of its uterine fibroids drug relugolix, Myovant has sold the regional rights off to Hungarian biotech Gedeon Richter. Comprising $40 million in upfront, $40 million in regu... |
| 24.06.2019 | Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | SAN FRANCISCO, June 24, 2019 -- (PRNewswire) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious me... |
| 24.06.2019 | Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares | SAN FRANCISCO, June 24, 2019 -- (PRNewswire) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious me... |
| 13.12.2018 | Akero Therapeutics Raises $70M in Financing | Akero Therapeutics, Inc., a San Francisco, CA-based biotechnology company developing transformational treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, closed $70m in Series B financing.
The round was l... |
| 13.12.2018 |
Versant Backed Akero Therapeutics Gets $70M More
| Akero Therapeutics, a biotechnology startup backed by San Diego's Versant Ventures, which developing treatments for non-alcohol steatohepatitis (NASH) and other serious metabolic diseases, has raised $70M in a Series B funding round. Accord... |
| 12.12.2018 | Akero Therapeutics Inks $70M in Series B |
SAN FRANCISCO, CA, Biotechnology company has closed $70 million in new Series B financing.
>> Click here for more funding data on Akero Therapeutics
>> To export Akero Therapeutics funding data to PDF and Excel, click here
... |
| 26.06.2018 | Term Sheet — Tuesday, June 26 | VENTURE MEETS CRYPTO
Good morning, Term Sheet readers.
Paid Content You can't secure what you can't see From ExtraHop
As I noted then, despite talk of cryptocurrency projects being scams and/or pump and dump schemes, VCs were warming up to ... |
| 25.06.2018 | Akero picks up $65M to advance Amgen-licensed NASH drug | Akero Therapeutics raised $65 million in series A financing to advance its lead program, long-acting fibroblast growth factor 21 (FGF21) analog, for the treatment of nonalcoholic steatohepatitis (NASH).
Sponsored by Agilent Technologies
How... |
| 25.06.2018 | Akero picks up $65M to advance Amgen-licensed NASH drug | Akero Therapeutics raised $65 million in series A financing to advance its lead program, long-acting fibroblast growth factor 21 (FGF21) analog, for the treatment of nonalcoholic steatohepatitis (NASH).
The Cambridge, Massachusetts-based bi... |
| 25.06.2018 | Akero Therapeutics Closes $65 Million Series A | Akero Therapeutics, Inc., a biotechnology company focused on transforming the treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, today announced the completion of a $65 million Series A financing. The fi... |
| 25.06.2018 | Akero Therapeutics Closes $65M Series A |
CAMBRIDGE, MA, Biotechnology company focused on transforming the treatment of non-alcoholic steatohepatitis and other serious metabolic diseases, completed a $65 million Series A round.
>> Click here for more funding data on Akero ... |
| 25.06.2018 | Akero Therapeutics Closes $65M Series A Financing | Akero Therapeutics, Inc., a Cambridge, MA-based biotechnology company focused on treatment of non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases, completed a $65m Series A financing.
The round was co-led by Apple Tree... |
